ABSTRACT
INTRODUCTION
A full understanding of the modes of action of the metal-based antitumoral drugs requires the detailed study of A number of Ru(III) complexes exhibit antitumor activities in animal models /1/. Two anticancer ruthenium (III) complexes, with imidazole and indazole ligands are highly active compared to other ruthenium(ill) compounds. Both of these complexes show excellent antitumor activity in various animal models/2/. The most promising complex is Hlnd[RuInd2Cl4 abbrev. Ru-ind (scheme 1) which is far less toxic in long term application than the imidazole analogue/3/. This has inspired considerable interest in the study of the biochelical behavior of the Ru-ind compounds including their interactions with serum proteins, which, are the primary target molecules, when metal compound is administered intravenously /4/. The preferred binding sites for the Ru(lll) complexes are at histidyl residues of the protein, presumably following the loss of one or more of the chloride ligands/5/. The major amount of ruthenium species (80-90 %) is bound to albumin and a much smaller amount to transferrin/4/. Apotransferrin may act as a natural carrier of the ruthenium drug and this has caused strong interest in the studies on Ru(iIl)-apotransferrin system/6, 7/. The coordination of ruthenium to apotransferrin can be used to enhance tumor uptake, since neoplastic cells, especially those in rapidly growing tumors, have a high iron requirement and display a large number of transferrin receptors on their membrane surfaces. Furthermore, it has been demonstrated that the apotransferrin-bound Ru-ind complex exhibits a significantly higher antitumor activity against human colon cancer cells when compared with the "free" species/4/. In contrast ruthenium-albumin bound species have no significant antitumor activity. experiments from a freshly prepared 5x10-4M aqueous solution. In all the experiments a. physiological buffer was used so that the final concentrations were 0.004 M NaH2PO4, 0.1M NaCI and 0.025M NaHCO3, pH 7.4.
Methods
Absorption spectra were recorded on a BECKMAN DU-650 spectrophotometer, and CD spectra on a JASCO J-715 spectropolarimeter. CD spectra were recorded over the range of 200-250 and 250-360 nm, 300-600 rim, using 0.! and 1.0 cm ceils respectively. Fluorescence measurements were carried out on an Warfarin has a weak fluorescence at 378 nm when excited at 335 rim, and the addition of HSA induced an increase in fluorescence intensity when warfarin binds to a single site in the protein /24/. Binding of ruthenium(III) complexes to HSA has an influence on warfarin binding site in albumin/9/. Hlnd[RuInd2Cl4] causes sevenfold decrease of a relative fluorescence intensity at 335 nm. However, the interaction of ruthenium compound with albumin already preincubated with warfarin quenches only slightly the intensity of this band (Fig. 4) . This The changes in the CD spectra (Fig. 5) confirm the results achieved in fluorescence measurements. The characteristic shape of the spectra for HSA preincubated with HInd/RulndzCl4/ is distinctly different from that of the native HSA, while the shape of the spectra obtained for HSA incubated prior with warfarin and then with ruthenium compound is almost the same although with decreased bands intensities.
Aquacobalamin (aqua-Bz) 16 .5% of the serum B2 is bound to albumin via imidazole groups of histidyl residues located in IIA and IliA subdomain/25/. Binding of aquacobalamin to HSA can be easily monitored by spectroscopic methods, especially the CD spectra. The CD spectra of aqua-form of vitamin Bj_ bound to HSA differ considerably from those of the free vitamin (see Fig. 6 ). The protein fractions bound with ruthenium were separated by gel-filtration chromatography. Ru contents in selection fractions were determined using the ICP(AES) method.
